Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Drives Into Immunotherapy With Early Blinatumomab BLA

This article was originally published in The Pink Sheet Daily

Executive Summary

Bispecific leukemia drug goes to FDA ahead of Phase III data in what could be a signature moment for the agency’s breakthrough designation program – and the company’s cancer deal-making.


Related Content

Merck’s Keytruda Opens Door, But Combination Trials Could Unlock Efficacy
Is The Time Finally Right For Bispecific Antibodies?
Amgen Gobbles Up Micromet In $1.16 Billion BiTE


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts